Login to Your Account



Other News To Note


Wednesday, April 4, 2012
• Genmab A/S, of Copenhagen, Denmark, said GlaxoSmithKline plc, of London, agreed to settle with Roche AG subsidiary Genentech Inc., of South San Francisco, and City of Hope concerning U.S. Patent Nos. 6,331,415 and 7,923,221 (the Cabilly II and III patents) relating to recombinant antibody production for ofatumumab. GSK is Genmab's development and commercial collaborator for the CD20 antibody. GSK initiated the case in October 2009. Terms of the agreement over the two patents, which are due to expire in December 2018, were not disclosed.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription